The Effect of Oxytocin Vaginal Gel on Vaginal Atrophy in Postmenopausal Women: a Randomized Controlled Trial

Overview

Journal BMC Womens Health

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2020 May 21

PMID 32429977

Citations 7

Authors

Ilnaz Zohrabi

Parvin Abedi

Somayeh Ansari

Elham Maraghi

Nader Shakiba Maram

Gholamreza Houshmand

Affiliations

Soon will be listed here.

Abstract

Background: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women.

Methods: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40-60, at least 1 year passed from their last menstrual period or the level of FSH > 40 IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention.

Results: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7 ± 7.18 vs. 3.69 ± 2.76, p = 0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76 ± 4.68 to 52.48 ± 7.54) in comparison to the placebo group (increased from 8.58 ± 4.35 to 13.25 ± 5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p = 0.0001). After 8 weeks, 88.6 and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p = 0.001).

Conclusion: The results of this study showed that eight- week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended.

Trial Registration: IRCT20160602028220N2.

Citing Articles

Injection of hyaluronic acid versus platelet rich plasma for treatment of vulvovaginal atrophy in post-menopausal females.

Ragy S, Kahky H, Elfakkar N, Nassar S, El-Husseiny R Arch Dermatol Res. 2025; 317(1):305.

PMID: 39853463 DOI: 10.1007/s00403-025-03820-z.

Oxytocin in growth, reproduction, restoration and health.

Moberg K Compr Psychoneuroendocrinol. 2024; 20:100268.

PMID: 39435014 PMC: 11492126. DOI: 10.1016/j.cpnec.2024.100268.

The Effect of Citrus Aurantium Vaginal Cream on Vaginal Atrophy in Postmenopausal Women: A Quasi-experimental Study.

Asgharpoor H, Hadizadeh-Talasaz F, Rahmani R, Rakhshandeh H, Rahmati Z Int J Community Based Nurs Midwifery. 2024; 12(1):32-43.

PMID: 38328013 PMC: 10844872. DOI: 10.30476/IJCBNM.2023.98670.2251.

The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis.

Farahat R, Salamah H, Mahmoud A, Hamouda E, Hashemy M, Hamouda H BMC Womens Health. 2023; 23(1):494.

PMID: 37716966 PMC: 10505316. DOI: 10.1186/s12905-023-02645-0.

Neural Functions of Hypothalamic Oxytocin and its Regulation.

Wang P, Wang S, Liu X, Jia S, Wang X, Li T ASN Neuro. 2022; 14:17590914221100706.

PMID: 35593066 PMC: 9125079. DOI: 10.1177/17590914221100706.

References

Jonasson A, Edwall L, Uvnas-Moberg K . Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 2011; 17(4):120-5. DOI: 10.1258/mi.2011.011030. View

Yaralizadeh M, Abedi P, Najar S, Namjoyan F, Saki A . Effect of Foeniculum vulgare (fennel) vaginal cream on vaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled trial. Maturitas. 2015; 84:75-80. DOI: 10.1016/j.maturitas.2015.11.005. View

Blaicher W, Gruber D, Bieglmayer C, Blaicher A, Knogler W, Huber J . The role of oxytocin in relation to female sexual arousal. Gynecol Obstet Invest. 1999; 47(2):125-6. DOI: 10.1159/000010075. View

Edwards D, Panay N . Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric. 2015; 19(2):151-61. PMC: 4819835. DOI: 10.3109/13697137.2015.1124259. View

Palacios S, Nappi R, Bruyniks N, Particco M, Panay N . The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018; 21(3):286-291. DOI: 10.1080/13697137.2018.1446930. View

Gutkowska J, Jankowski M, Mukaddam-Daher S, McCANN S . Oxytocin is a cardiovascular hormone. Braz J Med Biol Res. 2000; 33(6):625-33. DOI: 10.1590/s0100-879x2000000600003. View

. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007; 14(3 Pt 1):355-69. DOI: 10.1097/gme.0b013e31805170eb. View

Ludwig M, Leng G . Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006; 7(2):126-36. DOI: 10.1038/nrn1845. View

Uvnas-Moberg K, Petersson M . [Oxytocin, a mediator of anti-stress, well-being, social interaction, growth and healing]. Z Psychosom Med Psychother. 2005; 51(1):57-80. DOI: 10.13109/zptm.2005.51.1.57. View

10.

Wentzensen N, Trabert B . Hormone therapy: short-term relief, long-term consequences. Lancet. 2015; 385(9980):1806-8. DOI: 10.1016/S0140-6736(14)62458-2. View

11.

Naumova I, Castelo-Branco C . Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018; 10:387-395. PMC: 6074805. DOI: 10.2147/IJWH.S158913. View

12.

Parnan Emamverdikhan A, Golmakani N, Tabassi S, Hassanzadeh M, Sharifi N, Shakeri M . A survey of the therapeutic effects of Vitamin E suppositories on vaginal atrophy in postmenopausal women. Iran J Nurs Midwifery Res. 2016; 21(5):475-481. PMC: 5114791. DOI: 10.4103/1735-9066.193393. View

13.

Al-Saqi S, Uvnas-Moberg K, Jonasson A . Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health. 2015; 21(3):88-97. PMC: 4566058. DOI: 10.1177/2053369115577328. View

14.

Rad P, Tadayon M, Abbaspour M, Latifi S, Rashidi I, Delaviz H . The effect of vitamin D on vaginal atrophy in postmenopausal women. Iran J Nurs Midwifery Res. 2015; 20(2):211-5. PMC: 4387645. View

15.

Ibe C, Simon J . Vulvovaginal atrophy: current and future therapies (CME). J Sex Med. 2010; 7(3):1042-50. DOI: 10.1111/j.1743-6109.2009.01692.x. View

16.

Al-Eknah M, Homeida A, Galil A, Elbashir A . Oxytocin-induced biochemical changes in cervical mucus of the goat. Theriogenology. 1991; 36(1):143-8. DOI: 10.1016/0093-691x(91)90443-h. View

17.

Torky H, Taha A, Marie H, El-Desouky E, Raslan O, Moussa A . Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018; 21(2):174-178. DOI: 10.1080/13697137.2017.1421924. View

18.

Buckley S . Executive Summary of Hormonal Physiology of Childbearing: Evidence and Implications for Women, Babies, and Maternity Care. J Perinat Educ. 2016; 24(3):145-53. PMC: 4720867. DOI: 10.1891/1058-1243.24.3.145. View

19.

Petersson M, Lundeberg T, Sohlstrom A, Wiberg U, Uvnas-Moberg K . Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol. 1998; 357(6):701-4. DOI: 10.1007/pl00005227. View

20.

Sturdee D, Panay N . Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13(6):509-22. DOI: 10.3109/13697137.2010.522875. View